Α-Pyrrolidinopentiophenone

α-PVP is used by a variety of different routes of administration, including oral, insufflation, injection, vaporization, sublingual, and rectal. The dose range of α-PVP for therapeutic purposes was originally defined as 10 to 50mg, with a most-suitable dose of 20mg, whereas the recreational dose range is typically between 10 and 300mg. The effects of α-PVP onset after 10minutes, peak after 10 to 40minutes, and last 2 to 3hours. The effects of α-PVP include cocaine-like psychostimulant effects, euphoria, elevated mood, alertness, pleasurable rush, feeling "sped up", mania-like symptoms, enhanced energy, motivation and productivity, enhanced music enjoyment, mild sexual stimulation, insomnia, paranoia, hallucinations, and increased aggression and violence. In emergency settings, commonly observed effects have included psychosis-like state, agitation, aggression, hallucinations, abnormal heart rate, and vomiting. It also produces sympathomimetic effects, such as increased heart rate and blood pressure. == Adverse effects ==

α-PVP, like other stimulants, can cause hyperstimulation, paranoia, and hallucinations. α-PVP has been reported to be the cause, or a significant contributory cause of death in suicides and overdoses caused by combinations of drugs. α-PVP has also been linked to at least one death with pulmonary edema and moderately advanced atherosclerotic coronary artery disease when it was combined with pentedrone. According to Craig Crespi in the journal Case Reports in Psychiatry, "symptoms are known to easily escalate into frightening delusions, paranoid psychosis, extreme agitation, and a multitude of other altered mental states." These common adverse effects of α-PVP are in line with other stimulants. == Pharmacology ==

Pharmacodynamics α-PVP acts as a potent norepinephrine–dopamine reuptake inhibitor (NDRI), similarly to other NDRIs like methylphenidate, cocaine, and methylenedioxypyrovalerone (MDPV). Its values have been found to be 14 to 70nM for norepinephrine reuptake inhibition and 13 to 80nM for dopamine reuptake inhibition in rat brain synaptosomes and human embryonic kidney 293 (HEK293) cells expressing the monoamine transporters (MATs). In contrast to its effects on catecholamine reuptake, α-PVP has negligible effects on serotonin reuptake. It is one of the most potent dopamine reuptake inhibitors in vitro known. Pharmacokinetics The absorption of α-PVP is very rapid. In humans, the effects of the drug onset after 10minutes, peak between 10 and 40minutes, and last 2 to 3hours. α-PVP is said to be highly lipophilic due to its pyrrolidine ring, which in turn is said to markedly enhance its ability to permeate the blood–brain barrier relative to other cathinones. The distribution, metabolism, and elimination of α-PVP have been studied. == Chemistry ==

α-PVP gives no reaction with the Marquis reagent. It gives a grey/black reaction with the Mecke reagent. Detection in body fluids α-PVP may be quantified in blood, plasma, or urine by liquid chromatography-mass spectrometry to confirm a diagnosis of poisoning in hospitalized patients or to provide evidence in a medicolegal death investigation. Blood or plasma α-PVP concentrations are expected to be in a range of 10–50 μg/L in persons using the drug recreationally, >100 μg/L in intoxicated patients, and >300 μg/L in victims of acute overdosage. ==History==

α-PVP was first described in the literature in 1963. == Society and culture ==

Legal status α-PVP is banned in Estonia, Finland, France, Germany, Hungary, Russia, Ireland, Latvia, Lithuania, Netherlands, Poland, Romania, Slovenia, Sweden, the United Kingdom, Turkey, Norway, Australia α-PVP is a Schedule 9 prohibited substance under the Poisons Standard (July 2016). A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities. China As of October 2015, α-PVP is a controlled substance in China. European Union α-PVP was required to be banned by EU member states by 3 July 2017. Italy Cathinone and all structurally derived analogues (including pyrovalerone analogues) were classified as narcotics in January 2012. The temporary ban was then extended. Economics α-PVP is sometimes the active ingredient in recreational drugs sold as "bath salts". A laboratory for one county in Florida reported a steady rise in α-PVP detections in seized drugs from none in January–February 2014 to 84 in September 2014. == See also ==